Table 1_Genomic alterations and dynamic molecular residual disease monitoring predict path

29 stage II-III esophageal squamous cell carcinoma patients were prospectively enrolled to identify biomarkers for pathological response to neoadjuvant chemoimmunotherapy. Baseline tumor tissues were analyzed via 437-gene targeted sequencing, and serial plasma samples were profiled using a 2365-gene panel for tumor-informed molecular residual disease monitoring. Dijian Shen uploaded this dataset to figshare in April 2026 under a CC-BY-4.0 license.

Use Cases

• Predicting major pathological response based on baseline NOTCH1 mutation status.
• Evaluating the predictive value of post-treatment molecular residual disease status.
• Analyzing the association between chromosomal instability score and treatment outcome.
• Building integrated models combining genomic and ctDNA monitoring data for clinical decision support.

Strengths

• Data is from a prospective clinical study of 29 patients, providing a controlled research context.
• Genomic profiling used a 437-gene panel for baseline tissue and a 2365-gene panel for serial plasma monitoring.
• The description reports a specific predictive model achieving an AUC of 0.954.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small at 24.1 KB, indicating limited scope and sample size.

Provenance

Source

figshare

Collection Method

Prospective clinical study with genomic sequencing and ctDNA monitoring.

Freshness

Last updated 2026-04-30 05:39:52; freshness should be verified.